Kangmei Pharmaceutical: Net profit of 708 million in the first half year increased by 62.48% over the same period of last year

In the first half of the year, the company's main business income was RMB 5,313,317,100, an increase of 83.11% over the same period of the previous year, and its operating profit was RMB 835,851,600, an increase of 46.52% over the same period of the previous year, and the net profit attributable to the parent company's owner was RMB 704,957,700. The previous year increased by 62.48%.

The main work in the first half of 2012:

During the reporting period, the company’s “Cormico China Chinese Medicines Price Index” compiled by the company passed the expert review in Puning, Guangdong. This is the only national price index indexed by the National Development and Reform Commission that was compiled this year by the State Council to support the development of private economy. The only national price index indexed by large-scale private enterprises is the one of the 12 national-level key commodity prices.

During the reporting period, the company signed a cooperation agreement with PICC Capital Investment Management Co., Ltd. and China National People's Health Insurance Co., Ltd. to jointly establish a health management company and jointly launch health management services and sales of health products. At present, the establishment of new companies and other related procedures are in progress.

During the reporting period, the company had a total of 398 research and development projects, including 9 national and provincial-level scientific and technological projects, 8 new research and development projects for chemical drugs, 3 new drug research and development and quality standard setting projects, and ultra-fine Chinese medicines. There are 20 quality standard research projects, 163 research projects for traditional formulation granules and quality standards, 155 projects for the separation and preparation of traditional Chinese medicine standards, 8 health food development projects, and 32 functional food development projects.

During the reporting period, the company newly applied for 8 national and provincial-level science and technology projects, and 40 newly-established varieties, including 2 newly established chemical medicine varieties, 8 newly established varieties of traditional Chinese medicines, and 30 new varieties of health food and food products. Twenty-two items of food and health products were completed by the Provincial Department of Health.

During the reporting period, two post-doctoral research projects were conducted: “Comparison of the efficacy of Sinisan traditional decoction decoction and formula granules on liver injury model mice caused by two factors” and “Effect of sulfur fumigation on sulfur dioxide content in yam”. One local standard was formulated: "Technical Specifications for Micropowder Processing and Packaging of Chinese Herbal Medicines". In conjunction with the China Pharmacopoeia Commission and the Guangdong Provincial Institute of Food and Drug Control, two meetings on the “Study on Amendment of Traits of Chinese Herbs without Sulfur Fumigation and Herbal Medicine” were held.

During the reporting period, the company applied for registration of 54 trademarks, and obtained a total of 44 newly registered trademarks (of which 33 were from Kangmei Pharmaceutical and 11 were from Xinkaihe). The company applied for 9 invention patents (including 6 applications from Kangmei Pharmaceutical and 3 applications from Dadi Industry Co., Ltd.) and one new invention patent.

During the reporting period, the company won the “2012 Listed Companies in China's Top 100 Capital Brand Values”, “2012 China Listed Companies' Capital Brand Premium 100”, “Guangdong Poverty Alleviation Red Cotton Cup (Gold Award)” and “National Green Low Carbon Commitment to enterprises "and other honors.